Drawing for ID SOLUTIONS ONCOLOGY

USPTO serial 79410002

ID SOLUTIONS ONCOLOGY

Reviewed by CopyMark Law Group

Reg. 8105620Status 700Registered
Filing date
Status date
Registration date
Jan 20, 2026
Examiner
THOMAS, JULIE
Law office
Historical data usage

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ID SOLUTIONS ONCOLOGY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

J. Scott Gerien

J. Scott Gerien Dickenson, Peatman & Fogarty1500 First Street, Ste. 200Napa, CA 94559United States

Goods and services

ClassDescriptionStatusFirst use
001Biochemical preparations, namely, precursors intended for in vitro genetic engineering; diagnostic reagents for in vitro use for biochemistry, clinical chemistry and microbiology; chemical preparations for scientific purposes intended for use in DNA analysis, other than for medical use; enzymes, other than for medical use, for continuous, homogeneous and isothermal amplification processes for DNA-specific models; chemical genetic identity tests comprised of reagents for nonmedical purposes; reagents for nucleic acid amplification other than for medical or veterinary useACTIVE—
005Diagnostic test kits comprised of medical diagnostic agents, preparations and substances for detecting gene mutations implicated in cancers; in vitro test kits for detecting genetic defects for medical purposes; chemical preparations intended for use in DNA analysis for medical use; reagents for use in medical genetic testing; genetic identity tests comprising reagents for medical use; preparations for detecting genetic predispositions for medical use; reagents for nucleic acid amplification for medical useACTIVE—
009Laboratory apparatus for detecting genetic sequences; quantitative polymerase chain reaction (PCR) instrument for scientific use, namely, thermal cycler; laboratory apparatus and automatic machines for purifying nucleic acids, not for medical purposesACTIVE—
010DNA and RNA testing apparatus for medical use; genetic testing apparatus for medical use; quantitative polymerase chain reaction (PCR) instrument for medical use, namely, thermal cycler; samplers for medical use, namely, sample preparation device for medical diagnostic use; medical apparatus and automatic machines for purifying nucleic acids for medical useACTIVE—
042Research with respect to DNA sequencing technology; research in the field of DNA analysis technology; scientific research in the field of genetics and genetic engineering; structural and functional analysis of genomes; software as a service (SaaS) featuring software for the design of probes and primers for quantitative polymerase chain reaction (PCR) and interpretation of quantitative polymerase chain reaction (PCR) results in the field of health; software as a service (SaaS) featuring software for the design of probes and primers for quantitative polymerase chain reaction (PCR) and interpretation of quantitative polymerase chain reaction (PCR) results in the field of biology; software as a service (SaaS) featuring software for the design of probes and primers for quantitative polymerase chain reaction (PCR) and interpretation of quantitative polymerase chain reaction (PCR) results in the field of in vitro diagnostics; design, development and maintenance of software in the field of health; design, development and maintenance of software in the field of biology; design, development and maintenance of software in the field of in vitro diagnostics * ; all before-mentioned services only relating to applications in in vitro diagnostics of diseases and monitoring diseases *ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 24, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 10, 2026CHLDCHANGE OF OWNER RECEIVED FROM IB—
Aug 25, 2026NURCNOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED—
Aug 6, 2026LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Aug 5, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Aug 5, 2026FIMPFINAL DISPOSITION PROCESSED—
Aug 5, 2026LIMELIMITATION FROM THE IB EXAMINED AND ENTERED—
Aug 5, 2026COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Aug 5, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jul 16, 2026LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Jun 4, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 7, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Apr 20, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Apr 20, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Apr 20, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jan 20, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 20, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 11, 2025GPNXNOTIFICATION PROCESSED BY IB—
Dec 2, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 2, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 26, 2025OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Nov 26, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 25, 2025OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Oct 30, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 4, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 4, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 4, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 7, 2025RFNTREFUSAL PROCESSED BY IB—
May 22, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
May 22, 2025RFRRREFUSAL PROCESSED BY MPU—
Mar 27, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 26, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 6, 2025DOCKASSIGNED TO EXAMINER—
Dec 5, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 5, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 4, 2024LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Nov 21, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance